New hope for elderly lymphoma patients: drug cocktail targets aggressive cancer
NCT ID NCT07415980
First seen Feb 19, 2026 · Last updated Jun 21, 2026 · Updated 21 times
Summary
This study tests a combination of three drugs—polatuzumab vedotin, rituximab, and chidamide—in elderly patients (70+ or frail 60-69) with untreated diffuse large B-cell lymphoma that has two specific markers (MYC and BCL2). The goal is to see if this mix is safe and effective, aiming for complete remission. It is an early-phase trial with 68 participants, so results will guide future research rather than provide immediate new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE EXPRESSOR DLBCL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
polatuzumab vedotin, rituximab, and chidamide
What this could lead to
If successful, this could offer a new, less toxic treatment option for elderly patients with a hard-to-treat lymphoma type.
What could go wrong
This is an early-phase trial (phase 1b/2) with only 68 participants, so results may not confirm safety or effectiveness. The combination may cause side effects or fail to improve outcomes.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.